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LETTERS TO THE EDITOR
Supplementary data to the
study of ESRD Map in Japan
To the Editor: Our recent study [1] has added more
convincing evidence for renoprotection of angiotensin-
converting enzyme inhibitors (ACEIs) by asking whether
the use of ACEIs may explain our previously disclosed
important findings [i.e., regional variations in incidence
of end-stage renal disease (ESRD)] in Japan [2]. In this
study, we used the amounts of expense spent on ACEIs
as an explanation. This was, however, a surrogate marker
for a real use of ACEIs. Therefore, we next retrieved data
regarding the real use of ACEIs from Nephro-Database
in one large nephrology care center in Japan (Kimitsu
Hospital) [3]. The rationale for using this database was
that the hospital was the only nephrology center in its
catchment area, excluding patients and hospital-based
bias, and, more importantly, that the age-, sex- and under-
lying disease-adjusted cumulative incidence of ESRD was
significantly higher than other areas in Japan, for example,
in 1997, 178.9 per 1 million in the area, and 127.1 in Japan
as a whole, allowing us to compare ACEIs with other
potential risk factors in the area where progression of
renal failure was far accelerated. We conducted a retro-
spective chart review of 74 consecutive patients who had
started renal replacement therapy (RRT) between Janu-
ary 1993 and December 2000. Multiple logistic regression
Table 1. Multivariate logistic regression analysis of risk factors
associated with inception of renal replacement therapy
Odds ratio
Risk factors (95% CI) P
Sex (vs. female) 1.3 (1.1–2.1) 0.04
Age (vs. 40) 1.3 (1.0–2.8) 0.04
Late referral (vs. no)a 3.4 (1.4–3.6) 0.003
Baseline data
Serum creatinine (vs. 1.3 mg/dL) 2.1 (1.1–2.3) 0.004
Proteinuria level (vs. 1 g) 1.7 (1.9–2.5) 0.013
Hypertension (vs. no)b 2.4 (1.1–3.2) 0.004
Management
Anemia (vs. not on erythropoietin) 1.6 (1.2–2.1) 0.02
Use of ACEI as antihypertensive agents
(vs. below recommended dose) 0.5 (0.3–0.7) 0.003
Diet adherence (vs. good)c 1.3 (1.8–4.6) 0.03
a Late referral was defined as a case that started renal replacement therapy
within six months after an initial consult to renal outpatient clinic in the Kimitsu
Hospital
b Patients who had sitting systolic of diastolic blood pressure over 140/90
mm Hg, or who were receiving antihypertensive drugs were judged hypertensive
c Dietary adherence (good adherence was defined as daily urinary protein
intake less than 0.7 g and sodium intake less than 7 g, otherwise allocated to
poor adherence)
1920
analysis clearly demonstrated an independently favorable
role of “a usage of ACEIs (dose over the least officially
recommended one)” against inception of RRT among
antihypertensive agents (Table 1). Thus, we could confirm
the conclusion [1] in a local area of Japan on a micro
level, as well.
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Stopping progression
in familial juvenile
hyperuricemic nephropathy
with benzbromarone?
To the Editor: In a recent issue of Kidney International,
a landmark paper on familial juvenile hyperuricemic ne-
phropathy (FJHN) was published. Bleyer et al [1] describe
a large family with the disease, which is caused by a uromo-
dulin gene mutation. Chronic and progressive renal failure
was the most prominent clinical feature. Despite treat-
ment with allopurinol, loss of creatinine clearance (CrCl)
exceeded 3 mL/min/year.
Hyperuricemia in FJHN is caused by reduced fractional
excretion of uric acid (FEUA). Whereas allopurinol does
not affect FEUA, benzbromarone normalizes it in FJHN
[2]. We treated two FJHN patients with a combination of
allopurinol adjusted to renal function and benzbromarone
